Big Healthcare Stocks With a Positive Return Over the Past Week

Wall St. Watchdog reveals information about those large cap companies in the Healthcare sector that have had a positive return over the past week, in spite of the overall market’s dive.

  • MAKO Surgical Corp. (NASDAQ:MAKO): This company’s stock has returned 20.18% over the week-to-date period. The stock recently traded at $28.88 and its market capitalization is $1,182,909,000. About the company: MAKO Surgical Corp. is a medical device company. The Company offers robotic-ARM solutions and implants for minimally invasive orthopedic knee procedures.
  • Medicis Pharmaceutical Corporation (NYSE:MRX): This company’s stock has returned 16.36% over the week-to-date period. The stock recently traded at $37.34 and its market capitalization is $2,305,260,000. About the company: Medicis Pharmaceutical Corporation provides pharmaceuticals focusing on the treatment of dermatological, pediatric, and podiatric conditions, as well as aesthetics medicine. The Company has branded prescription products in therapeutic categories such as acne, asthma, eczema, fungal infections, hyperpigmentation, photoaging, psoriasis, and rosacea.
  • Pharmasset, Inc. (NASDAQ:VRUS): This company’s stock has returned 10.48% over the week-to-date period. The stock recently traded at $117.65 and its market capitalization is $4,374,708,000. About the company: Pharmasset, Inc. is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus, hepatitis B, and hepatitis C.
  • Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): This company’s stock has returned 6.65% over the week-to-date period. The stock recently traded at $31.13 and its market capitalization is $1,939,948,000. About the company: Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company’s primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.
  • Masimo Corporation (NASDAQ:MASI): This company’s stock has returned 6.34% over the week-to-date period. The stock recently traded at $25.01 and its market capitalization is $1,494,590,000. About the company: Masimo Corporation designs, develops and licenses medical signal processing and sensor technology for the noninvasive monitoring of physiological parameters. The Company’s first products are designed to improve the effectiveness of pulse oximetry by overcoming the inability of current monitors to precisely measure the levels of arterial blood oxygen saturation and low arterial blood flow.
  • Elan Corporation, plc (ADR) (NYSE:ELN): This company’s stock has returned 6.04% over the week-to-date period. The stock recently traded at $10.01 and its market capitalization is $5,685,122,000. About the company: Elan Corporation plc is a specialty pharmaceutical company. The Group’s drug delivery technologies are designed to aid and control the absorption and utilization of active pharmaceutical compounds. Elan’s Pharmaceutical division focuses on the discovery, development and commercialization of products in the areas of acute care, pain management, infectious diseases and neurology.
  • Acorda Therapeutics Inc. (NASDAQ:ACOR): This company’s stock has returned 4.85% over the week-to-date period. The stock recently traded at $25.53 and its market capitalization is $1,012,461,000. About the company: Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.
  • Perrigo Company (NASDAQ:PRGO): This company’s stock has returned 4.17% over the week-to-date period. The stock recently traded at $85.45 and its market capitalization is $7,923,446,000. About the company: Perrigo Company manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company’s customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson’s, CVS, and Target, and major wholesalers such as Super Valu and McKesson.
  • Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): This company’s stock has returned 4.07% over the week-to-date period. The stock recently traded at $8.94 and its market capitalization is $1,180,026,000. About the company: ARIAD Pharmaceuticals, Inc. discovers, develops, and commercializes small-molecule drugs to treat aggressive cancers. The Company’s first product candidate is an investigational mTOR inhibitor. ARIAD’s second product candidate is an investigational pan BCR-ABL inhibitor for treatment of blood cancers.
  • Valeant Pharmaceuticals Int (NYSE:VRX): This company’s stock has returned 3.86% over the week-to-date period. The stock recently traded at $40.41 and its market capitalization is $11,760,810,000. About the company: Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.
  • Volcano Corporation (NASDAQ:VOLC): This company’s stock has returned 3.72% over the week-to-date period. The stock recently traded at $28.42 and its market capitalization is $1,491,603,000. About the company: Volcano Corporation develops, manufactures, and commercializes medical devices. The Company’s products include intravascular ultrasound catheters and Functional Measurement guide wires used to diagnose and assess diseases of the coronary and peripheral vasculature.
  • Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): This company’s stock has returned 3.37% over the week-to-date period. The stock recently traded at $44.45 and its market capitalization is $9,156,604,000. About the company: Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.

(Note: Selected financial data are sourced from screener.co.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>